Draft Guidance on Timolol Maleate

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Timolol Maleate

Form/Route: Tablet/Oral

Recommended studies: 2 studies

1. Type of study: Fasting  
   Design: Single-dose, two-way crossover in-vivo  
   Strength: 20 mg  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments:

_______________________________________________________________________

2. Type of study: Fed  
   Design: Single-dose, two-way crossover in-vivo  
   Strength: 20 mg  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments: Please refer to the Amantadine Hydrochloride Draft Guidance for additional information regarding fed studies.

________________________________________________________________________

Analytes to measure (in appropriate biological fluid): Timolol in plasma

Bioequivalence based on (90% CI): Timolol

Waiver request of in-vivo testing: 5 mg and 10 mg based on (i) acceptable bioequivalence studies on the 20 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths. Please refer to Mirtazapine Tablet Draft Guidance for additional information regarding waiver of in-vivo testing.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Jun 2013